We are live on ! Find out more
VYGR icon

Voyager Therapeutics

106 hedge funds and large institutions have $308M invested in Voyager Therapeutics in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

71% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 21

68% more capital invested

Capital invested by funds: $184M → $308M (+$124M)

40% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $913K

31% more funds holding

Funds holding: 81106 (+25)

6.72% more ownership

Funds ownership: 55.01%61.73% (+6.7%)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
106
Holders Change
+25
Holders Change %
+30.86%
% of All Funds
1.66%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
41
Increased
36
Reduced
21
Closed
16
Calls
$1.27M
Puts
$913K
Net Calls
+$361K
Net Calls Change
+$1.05M
Name Holding Trade Value Shares
Change
Change in
Stake
EC
1
EcoR1 Capital
California
$44.1M
AC
2
Armistice Capital
New York
$41.5M +$1.03M +100,000 +3%
BlackRock
3
BlackRock
New York
$28.4M +$17.1M +1,653,613 +201%
Vanguard Group
4
Vanguard Group
Pennsylvania
$28.3M +$5.29M +511,146 +26%
FCM
5
Farallon Capital Management
California
$14.8M +$5.12M +495,000 +62%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$14.1M +$3.4M +328,516 +36%
EAM
7
Erste Asset Management
Austria
$12.1M -$310K -30,000 -3%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$10.9M +$3.31M +319,501 +51%
Morgan Stanley
9
Morgan Stanley
New York
$8.97M +$5.21M +503,903 +181%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$8.24M -$235K -22,696 -3%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$6.76M +$3.28M +317,000 +116%
Federated Hermes
12
Federated Hermes
Pennsylvania
$6.74M -$179K -17,330 -3%
State Street
13
State Street
Massachusetts
$6.24M +$4.66M +450,767 +479%
Marshall Wace
14
Marshall Wace
United Kingdom
$5.37M +$4.16M +402,280 +600%
HIM
15
Hillsdale Investment Management
Ontario, Canada
$4.13M +$3.73M +360,850 New
JP Morgan Chase
16
JP Morgan Chase
New York
$4.07M -$48.2K -4,658 -1%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$3.82M +$1.07M +103,548 +45%
GC
18
Globeflex Capital
California
$3.74M +$3.01M +290,791 +805%
Renaissance Technologies
19
Renaissance Technologies
New York
$3.58M +$1.87M +180,700 +137%
IC
20
Ikarian Capital
Texas
$3.44M +$3.1M +300,000 New
Northern Trust
21
Northern Trust
Illinois
$3.39M +$2.17M +210,133 +244%
FT
22
Fiduciary Trust
Massachusetts
$2.93M +$33.7K +3,257 +1%
Citadel Advisors
23
Citadel Advisors
Florida
$2.53M +$1.21M +117,282 +113%
Invesco
24
Invesco
Georgia
$2.3M +$2.08M +201,072 New
Assenagon Asset Management
25
Assenagon Asset Management
Luxembourg
$2.28M +$893K +86,327 +76%

VYGR Hedge Fund Activity: Q2 2023 in Review

106 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2023, worth a combined $308M — up 68% from $184M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new VYGR positions and 16 closed out — a net gain of 25 holders — while 36 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock, adding an estimated $17.1M. The largest seller was TRV GP III, exiting entirely with an estimated $24.6M sold.

  • 106 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2023, up from 81 in Q1 2023.
  • Funds reported $308M of Voyager Therapeutics stock for Q2 2023, up 68% quarter-over-quarter.
  • 41 funds opened new Voyager Therapeutics positions in Q2 2023 and 16 closed out, a net change of +25 holders.
  • The largest Voyager Therapeutics buyer in Q2 2023 was BlackRock, an estimated $17.1M added.
  • The largest Voyager Therapeutics seller in Q2 2023 was TRV GP III, an estimated $24.6M sold.

Based on aggregated 13F filings for Q2 2023.